Management of Acromegaly With Pasireotide LAR: A Case Study of Sustained Biochemical Control and Tumor Volume Reduction Without Worsening of Glycemia
ABSTRACT: Objective: Pasireotide long-acting release (LAR), a next-generation, multireceptor-targeted somatostatin analogue with high binding affinity to somatostatin receptor type 5, has been shown to be superior to octreotide LAR in inducing biochemical control in a multicenter, phase III clinical...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-01-01
|
| Series: | AACE Clinical Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2376060520305927 |